AndroGel Pediatric (Under 12): School and Activity Considerations

Why the FDA Issued a Black-Box Warning for Children

The FDA added a black-box warning to all topical testosterone gel products, including AndroGel 1% and AndroGel 1.62%, after receiving reports of children developing signs of virilization following inadvertent skin-to-skin contact with an adult using the medication. The FDA safety communication states: "Virilization has been reported in children who were secondarily exposed to testosterone gel."

The agency's 2009 action followed a series of case reports, including children aged 9 months to 5 years who developed pubic hair, clitoral enlargement, penile growth, or advanced bone age after contact with a caregiver's application site. No child under 12 should apply testosterone gel. The risk is entirely from unintentional transfer.

What Makes Transfer Happen

Testosterone gel is an alcohol-based formulation that deposits testosterone on the surface of the skin. The alcohol carrier evaporates within minutes, but the testosterone itself remains on the skin in a transferable form. Research published in Clinical Endocrinology confirmed that skin-to-skin contact, even through clothing in some cases, can deposit pharmacologically relevant amounts of testosterone onto a child's skin.

The transfer risk is highest in the first two hours after application if the site has not been washed. Hugging, wrestling, sharing a bed, or a child sitting on a caregiver's lap can all produce contact sufficient to cause measurable serum testosterone elevation in the child.

Serum Testosterone Levels Seen in Transfer Cases

In documented transfer cases reviewed by the FDA, affected children showed serum testosterone levels well above the normal prepubertal range of <10 ng/dL. Several cases described levels exceeding 100 ng/dL, a concentration associated with visible virilization when sustained. A case series in Pediatrics (PMID 18977954) described four boys aged 4 to 5 years with serum testosterone between 61 and 718 ng/dL after household exposure to topical testosterone; all four showed accelerated bone age on wrist radiographs.

Documented Clinical Signs of Accidental Exposure in Children Under 12

Pediatric virilization from testosterone transfer follows a predictable sequence. Signs can appear within weeks of regular exposure.

Early Signs (Weeks 2 to 8)

• Acne on the face or back
• Oily skin
• Body odor inconsistent with the child's age
• Mild pubic or axillary hair

The Endocrine Society's clinical practice guideline on androgen deficiency notes that even brief supraphysiologic androgen exposure in prepubertal children can trigger gonadotropin-independent pseudo-puberty, meaning the hypothalamic-pituitary axis is bypassed entirely.

Later Signs (Weeks 8 Onward)

• Penile or clitoral enlargement
• Deepening of the voice
• Accelerated linear growth
• Aggressive or emotionally labile behavior reported by teachers or school staff

Any of these signs in a child under 8 years old warrants same-day endocrinology evaluation. Bone age radiography (a left-hand X-ray) should be obtained at that visit. A 2019 review in JAMA Pediatrics confirmed that accelerated bone age from androgen excess, if uncorrected early, reduces predicted adult height by an average of 4 to 6 cm.

School-Day Protocol for Caregivers Who Use AndroGel

Managing AndroGel use when a child under 12 attends school requires a structured daily routine. The application timing and clothing choices made at home directly affect the child's classmates and teachers as much as the child.

Recommended Morning Routine

The safest practice is for the AndroGel user to apply the gel immediately after the child leaves for school or the bus, not before. The FDA-approved AndroGel prescribing information specifies that caregivers should wash their hands thoroughly with soap and water after application and cover the application site with clothing before any contact with children.

A practical morning sequence:

1. Child departs for school.
2. Caregiver applies AndroGel to shoulders or upper arms (the labeled sites).
3. Caregiver waits five minutes for the alcohol carrier to dry.
4. Caregiver washes hands with soap and water for at least 20 seconds.
5. Caregiver covers the application site with a long-sleeved shirt.
6. If the caregiver picks up the child later, the site should be washed with soap and water before physical contact, especially hugging or carrying.

Communicating With the School

Parents and guardians should consider informing the school nurse, not necessarily the classroom teacher, that a household member uses topical testosterone. This protects the child if the nurse notices early virilization signs during routine screenings. The disclosure is medical, not mandatory in most states, but it creates a documented baseline. CDC guidance on school health services supports this kind of caregiver-nurse communication for children with household medication exposures.

School nurses who observe unexpected pubic hair, acne, or behavioral changes in a child under 10 should ask about household testosterone use as part of the differential assessment.

Physical Education, Sports, and Extracurricular Activity Rules

WADA and School Athletic Policies for Under-12 Athletes

Testosterone is a prohibited substance under the World Anti-Doping Agency (WADA) Prohibited List. WADA rules technically apply to athletes in organized competition regardless of age, though enforcement at the under-12 recreational level is inconsistent. The critical point is that a child who tests positive for elevated testosterone, even from accidental exposure, may face disqualification or investigation.

Most U.S. State high school athletic associations mirror WADA's prohibited substance framework. At the under-12 youth sports level, formal drug testing is rare, but any child with documented testosterone elevation should not participate in competitive sport until levels normalize to the prepubertal range (<10 ng/dL), both for fair competition reasons and for the child's own safety given the cardiovascular and musculoskeletal effects of supraphysiologic androgens.

Contact Sports and Skin-to-Skin Risk During Play

A child from a household with an AndroGel user poses a transfer risk to teammates in contact sports if the child themselves has residual testosterone on their skin from secondary transfer. Research in the Journal of Clinical Endocrinology and Metabolism demonstrated that tertiary transfer (from a secondarily exposed individual to a third person) is theoretically possible, though the concentrations involved are far lower than primary transfer.

For practical purposes, coaches and physical education teachers do not need to segregate a child from household testosterone exposure. The residual tertiary transfer risk is negligible if the child has washed with soap and water before school activities.

Swimming and Aquatic Activities

Pool time raises a specific question. Showering with soap before entering a pool removes residual surface testosterone effectively. The AndroGel prescribing information recommends that the adult user wait at least five to six hours after application before swimming or showering. For a child with secondary exposure, a thorough soap-and-water shower before the pool session is sufficient precaution.

Monitoring a Child With Suspected or Confirmed Exposure

Initial Laboratory and Imaging Workup

If a child under 12 is found to have any virilization signs, the following workup is standard per Endocrine Society guidelines on precocious puberty:

• Total serum testosterone (morning draw)
• LH and FSH (to distinguish gonadotropin-dependent from gonadotropin-independent puberty)
• DHEAS and 17-hydroxyprogesterone (to exclude adrenal causes)
• Bone age radiograph of the left hand and wrist
• Baseline height and weight with Tanner staging

The goal is to confirm that the elevation is exogenous (suppressed LH/FSH with elevated testosterone) rather than pathological central precocious puberty (elevated LH/FSH with elevated testosterone).

Frequency of Follow-Up

Once the exposure source is identified and removed, a study in the Journal of Pediatric Endocrinology and Metabolism (PMID 16445195) found that serum testosterone returned to prepubertal levels within four to twelve weeks in most cases. Bone age monitoring should continue every six months for two years to confirm that the accelerated maturation has arrested.

Height velocity should be measured at each visit. If bone age advancement exceeds two standard deviations above chronological age after exposure has ended, a pediatric endocrinologist may consider GnRH agonist therapy to protect adult height potential, as described in the 2008 Endocrine Society CPG on precocious puberty.

What Teachers and School Staff Should Know

Teachers and school support staff are not expected to diagnose or manage testosterone exposure. Their role is observation and referral. The following behavioral and physical changes in a child under 10 should prompt a conversation with the school nurse and a call to parents:

• New acne appearing before age 8
• Body odor inconsistent with age
• Aggressive outbursts or mood swings that represent a clear change from baseline behavior
• Reports of genital discomfort or visible changes noted by the child

These observations should be documented in the child's health record with dates. The American Academy of Pediatrics policy on school health services supports structured nurse-teacher communication pathways for exactly this kind of concern.

Teachers do not need to ask about household medications directly. That question belongs to the school nurse or the child's pediatrician. The teacher's job is to notice and report, not to investigate.

If a Child Is Accidentally Prescribed or Given Testosterone Gel

This scenario is rare but has occurred, typically through dispensing errors. The FDA MedWatch adverse event reporting system should be used for any confirmed case of a child under 12 receiving a testosterone prescription or having testosterone gel applied to their own skin intentionally.

The immediate management steps are:

1. Wash the application site with soap and water immediately.
2. Contact Poison Control (1-800-222-1222 in the U.S.) for real-time guidance.
3. Bring the child to a pediatric emergency department if any acute symptoms are present (agitation, priapism, vomiting).
4. Obtain serum testosterone within 24 hours.
5. Report the dispensing error to the prescribing physician and the pharmacy.

A pharmacovigilance analysis in Drug Safety (PMID 22077504) identified pediatric testosterone exposure as one of the top ten preventable medication errors involving hormonal preparations in outpatient settings between 2000 and 2010.

Caregiver Checklist Before the Child Returns Home From School

The end-of-school pickup is a high-risk window if the caregiver applied AndroGel that morning and has not washed. The following checklist addresses the most common failure points:

• Did you apply AndroGel fewer than six hours ago? Wash the application site before hugging the child.
• Are you wearing a shirt that covers the application site completely? If not, change before pickup.
• Did you wash your hands after application this morning? If you applied gel to your hands or handled the tube without gloves, re-wash now.
• Will the child sit in your lap in the car? If so, a barrier garment (long-sleeved shirt) over the application site is required.

The FDA's consumer guide to testosterone gel safety lists these same precautions and notes that transfer can occur through a thin cotton shirt if the shirt presses directly against a child's skin for a prolonged period.

Long-Term Outlook for Children With Resolved Exposure

Children whose testosterone exposure is caught early and stopped promptly generally do well. A follow-up study in Hormone Research in Paediatrics (PMID 21659742) followed 11 children with exogenous testosterone exposure over 24 months after removal of the source. All 11 showed regression of virilization signs; 9 of 11 had bone age within one standard deviation of chronological age at the 24-month mark.

The two children with persistent bone age advancement had been exposed for more than 18 months before diagnosis. This underscores the value of early recognition, which depends directly on caregivers, teachers, and nurses knowing what to look for.

Adult height prediction for children with brief (<6 months) exposure and minimal bone age advancement is generally not altered significantly. Prolonged or unrecognized exposure carries a measurable height reduction risk of 3 to 8 cm based on the degree of bone age advancement at the time of detection.